SCHEMBL3947795

SCHEMBL3947795

COc1cc(C(=O)c2c(C)c(C(=O)O)c3cc(NC(C)=O)ccn23)ccc1N

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 1/20 0.38
▸ MAPT P10636 4/20 0.36
▸ ALDH1A1 P00352 3/20 0.35
▸ MEN1 O00255 3/20 0.35
▸ KMT2A Q03164 3/20 0.35
▸ HPGD P15428 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ HDAC1 Q13547 1/20 0.35
▸ KDM4E B2RXH2 3/20 0.34
▸ TUBB4A P04350 1/20 0.34
▸ TUBB P07437 1/20 0.34
▸ TUBA3C P0DPH7 1/20 0.34
▸ TUBA1B P68363 1/20 0.34
▸ TUBA4A P68366 1/20 0.34
▸ TUBB4B P68371 1/20 0.34
▸ TUBB3 Q13509 1/20 0.34
▸ TUBB2A Q13885 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3947293 0.90 ALDH1A1 (0.36) POLBMAPTALDH1A1MEN1KMT2A
SCHEMBL3945586 0.85 KDM4E (0.40) POLBMAPTALDH1A1MEN1KMT2A
SCHEMBL3952753 0.82 ALDH1A1 (0.36) MAPTALDH1A1MEN1KMT2AHPGD
SCHEMBL2515131 0.82 ALDH1A1 (0.45) MAPTALDH1A1MEN1KMT2AHPGD
SCHEMBL5739182 0.78 POLB (0.39) POLBMAPTALDH1A1MEN1KMT2A
SCHEMBL3953363 0.78 ALDH1A1 (0.38) MAPTALDH1A1KMT2AHPGDLMNA
SCHEMBL3944747 0.77 ALDH1A1 (0.40) MAPTALDH1A1KMT2ALMNAHTT
SCHEMBL3943568 0.77 HTT (0.39) ALDH1A1LMNAHTTL3MBTL1TUBB4A
SCHEMBL3948474 0.76 KDM4E (0.41) MAPTALDH1A1MEN1KMT2AHPGD
SCHEMBL3948472 0.76 KDM4E (0.41) MAPTALDH1A1MEN1KMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7553845-B2 Substituted indolizine 1,2,3,6,7,8 derivatives, FGFs inhibitors, a method for the preparation thereof and pharmaceutical compositions containing said derivatives SANOFI-AVENTIS (FR) 2009-06-30 — — US disclosed
US-20060199962-A1 Substituted indolizine 1,2,3,6,7,8 derivatives, FGFs inhibitors, a method for the preparation thereof and pharmaceutical compositions containing said derivatives SANOFI-AVENTIS (FR) 2006-09-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060199962-A1 Substituted indolizine 1,2,3,6,7,8 derivatives, FGFs inhibitors, a method for the preparation thereof and pharmaceutical compositions containing said derivatives FGF1, FGF2, FGFR1 POLB 4747/4885MAPT 2703/4885ALDH1A1 724/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback